(Q43283574)

18 November 2017

title

The effect of raltegravir on the glucuronidation of lamotrigine (English)

1 reference

18 November 2017

1 reference

Matthijs van Luin

1

1 reference

18 November 2017

Angela Colbers

2

1 reference

18 November 2017

Corrien P W G M Verwey-van Wissen

3

1 reference

18 November 2017

Eleonora W J van Ewijk-Beneken-Kolmer

4

1 reference

18 November 2017

Mike van der Kolk

5

1 reference

18 November 2017

Arjen Hoitsma

6

1 reference

18 November 2017

Hugo Gomes da Silva

7

1 reference

18 November 2017

David M Burger

8

1 reference

18 November 2017

publication date

28 August 2009

1 reference

The Journal of Clinical Pharmacology

18 November 2017

published in

1 reference

18 November 2017

volume

49

1 reference

18 November 2017

issue

10

1 reference

18 November 2017

page(s)

1220-1227

1 reference

Raltegravir with optimized background therapy for resistant HIV-1 infection

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Special populations: the management of seizures in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Seizures in HIV-seropositive individuals: NIMHANS experience and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Lack of a significant drug interaction between raltegravir and tenofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

UDP-glucuronosyltransferases and clinical drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Sodium valproate acutely inhibits lamotrigine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Variation in glucuronidation of lamotrigine in human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

Biological rhythms in the absorption, distribution, metabolism and excretion of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009345689

21 January 2018

Identifiers

DOI

10.1177/0091270009345689

1 reference

18 November 2017

1 reference